American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献_第4页

When and How Long to Treat Chronic Lymphocytic Leukemia? 慢性淋巴细胞白血病何时治疗，需要多长时间？

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-24 DOI: 10.1200/EDBK-25-473656

Carsten U Niemann, Abraham Varghese, Talha Munir, Ellinor Goergen, Barbara Eichhorst

引用次数: 0

Rare Uterine Tumors: What to Do? 罕见的子宫肿瘤：该怎么办？

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1200/EDBK-25-473106

Erin Crane, Stéphanie Gaillard, Martee Leigh Hensley

引用次数: 0

Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward. 局部肌肉浸润性膀胱癌的围手术期治疗选择：向前迈进了一步。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-20 DOI: 10.1200/EDBK-25-472822

Maria J Ribal, Jonathan Rosenberg, Tarek Ajami, Antoni Vilaseca, Leilei Xia, Michal Sternschuss, Anne K Schuckman

{"title":"Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward.","authors":"Maria J Ribal, Jonathan Rosenberg, Tarek Ajami, Antoni Vilaseca, Leilei Xia, Michal Sternschuss, Anne K Schuckman","doi":"10.1200/EDBK-25-472822","DOIUrl":"10.1200/EDBK-25-472822","url":null,"abstract":"Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after radical cystectomy and pelvic lymph node dissection alone. In cisplatin-eligible patients, administration of neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been shown to improve overall survival (OS) and has become the standard of care. Nevertheless, approximately 40%-50% of patients will still experience disease recurrence after curative-intent treatment. Moreover, a significant proportion of patients with MIBC are ineligible for cisplatin and represent a challenging clinical scenario. In recent years, different strategies aiming to improve patient outcomes by incorporating immune checkpoint inhibitors in the treatment paradigm were explored. Two key management approaches emerged: neoadjuvant chemotherapy with risk-adapted adjuvant immunotherapy and universal perioperative immunotherapy-based treatment. We review the rationale, current evidence, challenges, and future directions for the perioperative management of muscle-invasive urothelial carcinoma.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472822"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration. 非小细胞肺癌的双特异性抗体：从靶向创新到现实世界的整合。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.1200/EDBK-25-472792

Jennifer W Carlisle, Zachary Wolner, Sagal Pannu, Carley Mitchell, Melinda Hsu, Ayesha Aijaz, Melissa Johnson, Abdul Rafeh Naqash

{"title":"Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.","authors":"Jennifer W Carlisle, Zachary Wolner, Sagal Pannu, Carley Mitchell, Melinda Hsu, Ayesha Aijaz, Melissa Johnson, Abdul Rafeh Naqash","doi":"10.1200/EDBK-25-472792","DOIUrl":"https://doi.org/10.1200/EDBK-25-472792","url":null,"abstract":"Bispecific antibodies have ushered in a transformative era in treating non-small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory disease subsets. Recent US Food and Drug Administration approvals-including amivantamab, an epidermal growth factor receptor (EGFR)/mesenchymal-epithelial transition factor-targeting monoclonal antibody for EGFR exon 20 insertions and frontline EGFR-mutant (Exon 19 and 21) NSCLC, and zenocutuzumab for tumors harboring neuregulin 1 fusions-highlight their expanding therapeutic footprint. However, a new spectrum of on-target toxicities and implementation challenges are essential considerations as part of this innovation. This review dissects the evolving clinical data for bispecific antibodies in NSCLC, focusing on amivantamab, and provides a practical framework for managing dermatologic, infusion-related, and class-specific adverse events. We explore quality-of-life outcomes, financial toxicity, and the role of subcutaneous formulations in improving patient adherence and treatment experience. Furthermore, we highlight an emerging PD-1/vascular endothelial growth factor-A bispecific antibody (ivonescimab) and its potential to reshape frontline therapy paradigms in NSCLC. By integrating clinical trial evidence with real-world considerations, this review aims to equip oncologists with the tools to optimize the use of bispecific antibodies in NSCLC and guide future therapeutic integration.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472792"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Driving Knowledge to Action: Building a Better Future With Artificial Intelligence-Enabled Multidisciplinary Oncology. 将知识转化为行动：用人工智能支持的多学科肿瘤学建立更美好的未来。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-02 DOI: 10.1200/EDBK-25-100048

Arturo Loaiza-Bonilla, Nikhil Thaker, Caroline Chung, Ravi Bharat Parikh, Shawn Stapleton, Piotr Borkowski

{"title":"Driving Knowledge to Action: Building a Better Future With Artificial Intelligence-Enabled Multidisciplinary Oncology.","authors":"Arturo Loaiza-Bonilla, Nikhil Thaker, Caroline Chung, Ravi Bharat Parikh, Shawn Stapleton, Piotr Borkowski","doi":"10.1200/EDBK-25-100048","DOIUrl":"https://doi.org/10.1200/EDBK-25-100048","url":null,"abstract":"Artificial intelligence (AI) is transforming multidisciplinary oncology at an unprecedented pace, redefining how clinicians detect, classify, and treat cancer. From earlier and more accurate diagnoses to personalized treatment planning, AI's impact is evident across radiology, pathology, radiation oncology, and medical oncology. By leveraging vast and diverse data-including imaging, genomic, clinical, and real-world evidence-AI algorithms can uncover complex patterns, accelerate drug discovery, and help identify optimal treatment regimens for each patient. However, realizing the full potential of AI also necessitates addressing concerns regarding data quality, algorithmic bias, explainability, privacy, and regulatory oversight-especially in low- and middle-income countries (LMICs), where disparities in cancer care are particularly pronounced. This study provides a comprehensive overview of how AI is reshaping cancer care, reviews its benefits and challenges, and outlines ethical and policy implications in line with ASCO's 2025 theme, Driving Knowledge to Action. We offer concrete calls to action for clinicians, researchers, industry stakeholders, and policymakers to ensure that AI-driven, patient-centric oncology is accessible, equitable, and sustainable worldwide.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100048"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Art of Oncology Education and Knowledge Sharing-It is All About the "How". 肿瘤学教育与知识分享的艺术——全在于“如何”。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1200/EDBK-25-471836

Guilherme Sacchi de Camargo Correia, Lori J Rosenstein, Rohit Gosain, Rami Manochakian

{"title":"The Art of Oncology Education and Knowledge Sharing-It is All About the \"How\".","authors":"Guilherme Sacchi de Camargo Correia, Lori J Rosenstein, Rohit Gosain, Rami Manochakian","doi":"10.1200/EDBK-25-471836","DOIUrl":"https://doi.org/10.1200/EDBK-25-471836","url":null,"abstract":"In the rapidly evolving field of oncology, education and knowledge sharing have become essential aspects of oncology practice and must-needed tools to help patients conquer cancer. Oncology education is an art that needs to be mastered by applying scientific learning methods through structured frameworks into it, in order to have an impact. To effectively educate and share knowledge with oncology professionals, we propose following a \"chain of education\". This chain consists of five links that are essential for creating a successful educational activity: \"who\", \"why\", \"where\", \"what\", and \"how\". By following the \"chain of education\" through all links leading to the final key of how to educate, and guided by learning science principles, educators can optimize and enhance their teaching and knowledge-sharing skills and educate learners with more impact. Two common scenarios of medical education in oncology are the education of trainees and the education of community oncologists. In this article, we review them through the prism of the \"chain of education\". We discuss how using effective learning science principles can guide small changes that lead to significant impacts in trainees' education and can also leverage social media platforms in the education of community oncologists. Alongside this described framework, we briefly review some available oncology education resources, and we discuss incorporating the \"chain of education\" into future technologies.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e471836"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporating Targeted Therapy Into Neuro-Oncology Practice. 将靶向治疗纳入神经肿瘤学实践。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1200/EDBK-25-473324

Marjolein Geurts, Juan B Blaquier, Maarten Wijnenga, David O Kamson, Macarena I de la Fuente

{"title":"Incorporating Targeted Therapy Into Neuro-Oncology Practice.","authors":"Marjolein Geurts, Juan B Blaquier, Maarten Wijnenga, David O Kamson, Macarena I de la Fuente","doi":"10.1200/EDBK-25-473324","DOIUrl":"https://doi.org/10.1200/EDBK-25-473324","url":null,"abstract":"The integration of targeted therapies into neuro-oncology is revolutionizing the management of primary CNS malignancies. Advances in sequencing technologies and the incorporation of molecular alterations into CNS tumor classification have led to more precise tumor prognosis and enabled the identification of actionable oncogenic drivers. However, challenges such as drug delivery, tumor and microenvironment heterogeneity, and limitations of preclinical models complicate the selection of effective therapies. This review presents a comprehensive framework for optimizing drug selection in neuro-oncology. We discuss strategies to enhance drug development and improve clinical trial success, including window-of-opportunity trials and advanced imaging techniques. Additionally, we highlight recent advances in the treatment of isocitrate dehydrogenase-mutant gliomas, focusing on the INDIGO study and its role in the regulatory approval of vorasidenib. The review also examines the use of MAPK inhibitors, from BRAF inhibitors to PAN-RAF inhibitors, in both pediatric and adult patients, as well as novel investigational agents. Finally, we explore emerging targeted therapies for rarer oncogenic drivers, such as FGFR and NTRK alterations, emphasizing the need for CNS-specific drug development strategies.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473324"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating B-ALL in the Era of Blinatumomab. 在blinatumumab时代导航B-ALL。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1200/EDBK-25-472778

Sue Zupanec, Melissa Beauchemin, Rachel E Rau

{"title":"Navigating B-ALL in the Era of Blinatumomab.","authors":"Sue Zupanec, Melissa Beauchemin, Rachel E Rau","doi":"10.1200/EDBK-25-472778","DOIUrl":"https://doi.org/10.1200/EDBK-25-472778","url":null,"abstract":"Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)-positive adult B-ALL in 2018, its indications have since expanded after pivotal trials demonstrating significant efficacy. The BLAST and E1910 trials highlighted the benefit of blinatumomab in adults in MRD-positive and MRD-negative remission, respectively, with notable improvements in overall survival and relapse-free survival. In pediatric populations, studies such as the AALL1731 and a landmark trial in infants with KMT2A-rearranged B-ALL demonstrated striking reductions in relapse when blinatumomab was added to standard regimens. Similarly, in Philadelphia chromosome-positive B-ALL, blinatumomab-based regimens have enabled chemotherapy minimization while achieving durable remissions. Despite these advances, the rapid integration of blinatumomab into standard care poses challenges related to administration, toxicity management, and equitable access. Variability in inpatient observation durations, infusion bag sizes, home health availability, and handling of infusion-related complications underscore the need for standardized delivery models. Additionally, low-grade and long-term toxicities-such as neurotoxicity, cytokine release syndrome, and hypogammaglobulinemia-remain undercharacterized. Looking forward, research is focusing on optimizing the use of blinatumomab, including its integration into reduced-intensity or chemotherapy-free regimens, alternative dosing schedules, and subcutaneous administration. As clinical use expands, emphasis must shift toward developing equitable, patient-centered delivery strategies and understanding the full spectrum of toxicities to ensure optimal and accessible care for all patients with B-ALL.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472778"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care. 临床试验可及性实用指南：使试验参与成为护理标准。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-19 DOI: 10.1200/EDBK-25-100052

Hedyeh Ebrahimi, Jodie Allen, Yelak Biru, Ravin Garg, Christine Hodgdon, William K Oh, David Steensma, Sumanta K Pal, Therese Mulvey

{"title":"Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care.","authors":"Hedyeh Ebrahimi, Jodie Allen, Yelak Biru, Ravin Garg, Christine Hodgdon, William K Oh, David Steensma, Sumanta K Pal, Therese Mulvey","doi":"10.1200/EDBK-25-100052","DOIUrl":"https://doi.org/10.1200/EDBK-25-100052","url":null,"abstract":"Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this multidisciplinary perspective piece, stakeholders from patient advocacy, community oncology, industry, and academic medicine offer a collaborative overview of key challenges and practical solutions to improve trial accessibility. Patient advocates highlight the need to address language barriers, financial toxicity, and underrepresentation through community engagement and patient-centered trial design. Community oncologists underscore infrastructure limitations, generalist practice burdens, and misaligned trial offerings, calling for eligibility reform and cooperative trial models. Industry partners examine how overly restrictive criteria and inconsistent protocol practices hinder diversity and propose portfolio-wide strategies, such as protocol watch lists, for inclusive design. Academic oncologists focus on trial complexity, investigator burden, and limited generalizability, advocating for pragmatic and decentralized trial paradigms. Together, these perspectives underscore the shared responsibility across sectors to modernize clinical trial design, reduce access barriers, and ensure that trial participation becomes a standard and equitable component of cancer care.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100052"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing Barriers in Palliative Care for Rural and Underserved Communities. 解决农村和服务不足社区的姑息治疗障碍。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.1200/EDBK-25-472842

Matthias Weiss, Susan Sabo-Wagner, Julia Frydman, C S Pramesh

{"title":"Addressing Barriers in Palliative Care for Rural and Underserved Communities.","authors":"Matthias Weiss, Susan Sabo-Wagner, Julia Frydman, C S Pramesh","doi":"10.1200/EDBK-25-472842","DOIUrl":"https://doi.org/10.1200/EDBK-25-472842","url":null,"abstract":"Thirty-two million Americans live in rural counties and have no access to multidisciplinary cancer care, and patients with cancer describe a greater number of unfavorable social determinants of health (SDoH), experience more serious financial hardship as well as greater symptom burden, and are more likely to die of cancer. Delivering effective symptom management may be achieved through adoption of a hub and spoke model, which connects rural community care sites with a cancer center. Modern technologies (electronic medical record and virtual telehealth), advanced practice provider care models, and engagement in symptom management clinical trials can extend more optimal care to connected rural sites. Pragmatic examples of addressing these care barriers include systematic and proactive assessment of SDoH, supported by navigation and social services, and telehealth-enabled palliative care (PC). In low- and middle-income countries, access to supportive cancer care services is very limited, especially in rural areas. Digital health interventions, primarily limited to apps, and community health workers (trained volunteer care providers) have successfully enabled vital symptom management services. Access to PC, considered a basic human right, is unfortunately not available in many parts of the world, especially in rural areas of not only low- and middle-income but also high-income countries. Multiple approaches to deliver effective symptom management have been described but need to be tailored to the respective local health care infrastructure, resources, culture, and social, economic, and political environment.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472842"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0